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Abstract: Most patients with dementia receive care within primary care systems and have 
challenging medical and psychiatric issues. Their dementia related symptoms are often not 
recognized by the primary care system; they suffer from multiple chronic medical conditions; 
receive numerous psychotropic medications including anticholinergics; and display clinically 
relevant behavioral and psychological symptoms. Improving the care for such vulnerable patients 
demands supporting the primary care system with various resources, including dementia care 
managers, access to and coordination with interdisciplinary dementia specialists, and a feasible 
dementia screening and diagnosis process.
Understanding primary care clinics as a complex adaptive system may enhance our capac-
ity to deliver a ﬂ  exible supportive process using the above crucial resources to adequately 
assess and effectively manage patients with dementia. Such a complex adaptive system process 
would have the best probability of surviving the unknowable future challenges that will face 
the primary care system.
A global consensus of dementia epidemiologists estimates that a new patient is diag-
nosed with dementia every 7 seconds (Ferri et al 2005). In 2000, there were between 
3 and 7 million dementia cases in the US (Sloane et al 2002). It is anticipated that, 
if no scientiﬁ  c advances occur to alter the incidence and progression of dementia, 
between 8 and 13 million people in the US will be suffering from the syndrome by 
the year 2050 (Sloane et al 2002). Dementia is an acquired syndrome of decline in 
memory and at least one other cognitive domain, such as language, visuo-spatial or 
executive function, sufﬁ  cient to interfere with social or occupational functioning in 
an alert person (APA 1994). Alzheimer Disease (AD) is considered the most common 
type of dementia (APA 1994).
In this manuscript, we ﬁ  rst describe the burden of dementia and the current status 
of dementia care in primary care systems; second, we provide a clinically relevant 
review of currently available pharmacological interventions to manage the various 
symptoms of dementia; third, we describe an organizational theory, called complex 
adaptive system, and its potential application to enhance dementia care within primary 
care systems; and ﬁ  nally, we provide an example of a recent successful application 
of this theory.
Dementia burden
Dementia causes a high burden of suffering for patients and their families (Boustani 
et al 2003a). For patients, in addition to cognitive and functional deterioration, demen-
tia leads to behavioral and psychological complications, increased use of health and 
social services, complicated clinical management of other comorbid conditions, and 
increased risk for medical complications such as delirium, falls, motor vehicle crashes, 
incontinence, fractures, and infections. For family caregivers, dementia can lead to Clinical Interventions in Aging 2007:2(4) 632
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higher levels of anxiety, depression, use of psychotropic 
medications, sleep problems, and chronic fatigue (Boustani 
et al 2003a) (see Table 1). In 2003, dementia constituted 11% 
of total years lived with disability in people aged 60 years 
and older. This is more than cancer, stroke or cardiovascular 
disease (Ferris et al 2005). Currently, Medicare recipients 
with dementia account for 34% of Medicare spending, 
even though they constitute only 13% of the total Medicare 
beneﬁ  ciaries. By 2050, Medicare will be spending over 
$1 trillion on beneﬁ  ciaries with this syndrome (The Lewin 
Group, 2004).
The status of dementia care
in the primary care system
The majority of patients with dementia receive their care 
within a primary care system (Boustani et al 2005; Callahan 
et al 2006). In this health care setting, dementia prevalence 
is 2% among patients aged 65 to 69 years, 7% among those 
aged 70 to 79 years, and 17% among older adults aged 80 
and older (Boustani et al 2005). Research studies found that 
less than a third of these patients are recognized by the pri-
mary care system as having dementia (Boustani et al 2003a, 
2005). Patients with dementia suffer from numerous chronic 
medical conditions, receive multiple prescriptions includ-
ing psychotropic drugs, display a wide range of behavioral 
and psychological symptoms, and extensively utilize the 
health care system (Boustani et al 2003a; Callahan et al 
2006; Schubert et al 2006) (see Table 2). More than 20% 
of these patients with dementia are exposed to at least one 
deﬁ  nite anticholinergic medication and less than 10% are 
prescribed cholinesterase inhibitors (Schubert et al 2006). 
Unfortunately, the complicated medical and psychiatric needs 
of demented patients affect not only their own care but also 
the health of their informal caregivers (Guerriero Austrom 
et al 2004; Callahan et al 2006; Schubert et al 2006). Thus, 
enhancing the primary care of patients with dementia will 
require additional ﬁ  nancial, educational and social resources 
(Boustani et al 2005; Callahan et al 2006).
Managing the needs of dementia 
patients in primary care
Dementia is characterized by a complex interaction of cog-
nitive, functional, behavioral and psychological symptoms 
that decrease the quality of life for both the patient and the 
caregiver. Therefore, successful management needs to be 
composed of interventions for both. The scope of such inte-
grated management must include pharmacological therapies 
and psychosocial interventions that target the entire spectrum 
of dementia symptomatology. An efﬁ  cacious management 
would most likely stabilize or slow the cognitive decline; 
stabilize or prevent additional functional disability; and 
decrease the severity or delay the emergence of behavioral 
and psychological symptoms of dementia (BPSD) (See 
Table 3).
Managing cognitive symptoms
To date, the United States Federal Drug Agency (FDA) 
and the European Union Drug Evaluation Agency have 
approved two classes of medications for the treatment of AD, 
cholinesterase inhibitors (ChEIs) (Donepezil, Rivastigmine, 
Galantamine) and a NMDA receptor antagonist (Memantine). 
Recently, the two agencies approved the use of Rivastigmine, 
a ChEI, for patients with Parkinson Disease Dementia.
Table 1 Dementia symptomatology
Cognitive impairment:  Functional disability:
–Memory deﬁ  cit  –Basic ADL disability
–Language deﬁ  cit  –IADL disability
–Executive deﬁ  cit
–Visuospatial deﬁ  cit
–Stimulation recognition deﬁ  cit (agnosia)
Behavioral and psychological   Caregiver burden
symptoms:
–Apathy –Sleep  problem
–Depression/Dysphoria/Irritability –Mood  problem
–Anxiety –Coping  problem
–Agitation/Aggression
–Delusions/Hallucinations
–Elation/Euphoria
–Disinhibition
–Aberrant motor behavior
–Sleep disturbance
–Appetite/Eating disorders
Table 2 The status of dementia in primary care (Callahan CM 
et al 2006 Schubert CC et al 2006).
Variable  % or Mean (SD)
Mini mental status examination score  17.5 (5.2)
Number of chronic disease  2.4 (1.40)
Number of prescribed medications  5.1 (3.8)
Suffer from behavioral and psychological   80%
symptoms
Emergency visit or hospitalization within last   38%
6 months
Recognized cases  <25%
Receiving cholinesterase inhibitors  <10%
Receiving at least one psychotropic medication  >20%
Receiving at least one deﬁ  nite anticholinergic   >20%
medicationClinical Interventions in Aging 2007:2(4) 633
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ChEIs are generally considered the ﬁ  rst line treatment, 
especially in mild dementia. In comparison to placebo, 
6-month therapy with a ChEI has demonstrated statisti-
cally signiﬁ  cant positive effects on cognition (Boustani, 
M et al 2003a; 2003b). The level of improvement shown 
was approximately equivalent to a 5- to 10-month delay 
in the progression of the disease. Memantine is approved 
for the treatment of patients with moderate to severe AD 
(Mini Mental Status Examination <18). In comparison to 
placebo, Memantine produces a similar effect to ChEIs on 
patients’ cognition with a mean difference of 4 points on 
the Severe Impairment Battery (SIB) (SIB range is 0 to 100 
points) (Areosa Sastre A et al 2006). Moreover, Memantine 
has also been evaluated as an add-on (combined) therapy to 
ChEIs among patients with moderate to severe dementia and 
has led to a signiﬁ  cant cognitive difference of 3 points on 
the SIB (Areosa Sastre et al 2006). Treatment with ChEIs 
and Memantine may, however, lead to adverse effects such 
as nausea, vomiting, and diarrhea for ChEIs and headache, 
confusion and constipation for Memantine (Boustani M et al 
2003a, 2003b; Areosa Sastre A et al 2006).
Managing functional disability
Since there is a lack of universally accepted measures to 
evaluate the impact of ChEIs and Memantine on the func-
tional performance of patients with AD and other dementias, 
it is difﬁ  cult to appreciate the day to day impact of these 
medications on functional disability. In general, the effect 
of ChEI and Memantine on daily function appears minimal 
(Boustani et al 2003a, 2003b; Livingston and Katona 2004; 
Areosa Sastre et al 2006). However, using time to functional 
decline as an outcome measure and in comparison to pla-
cebo, Donepezil demonstrated a 5-month delay in such a 
decline (Boustani et al 2003a, 2003b). Furthermore, 34% 
of patients with moderate to severe AD did not decline 
functionally after 6 months of treatment with Memantine 
versus 20% of those receiving placebo (Livingston and 
Katona 2004).
Managing behavioral and psychological 
symptoms of dementia (BPSD)
The non-cognitive behavioral and psychological symptoms 
in dementia (BPSD) can be deﬁ  ned as verbal, vocal, or motor 
behavior that is inappropriate for the setting, and reﬂ  ects 
inadequate ability to cope with internal and/or environmental 
stressors. BPSD includes a heterogeneous range of psycho-
logical reactions, psychiatric symptoms, and behaviors. A 
variety of both internal and external stressors can be involved. 
More than 90% of patients with dementia will experience 
BPSD at some point during the course of their illness (Finkel 
et al 2000). Aggression is the most serious symptom and 
seems to be present in 30% of patients with dementia attend-
ing primary care clinics (Haupt et al 2000).
The current management of aggression is, at best, mod-
erately successful, even in controlled trials. One reason for 
the limited effectiveness of aggression management is the 
current focus on pharmacologic interventions used in the 
setting of an acute crisis. The traditional pharmacological 
management of BPSD in general and aggression in particular 
includes the use of typical and atypical neuroleptics, antide-
pressants, anticonvulsants, hypnotics, and ChEIs. However, 
these pharmacologic interventions have not been approved by 
the FDA for such therapy, their efﬁ  cacy is limited, and they 
produce numerous side effects (Schneider et al 2005; Sink 
et al 2005; Schneider et al 2006). Neuroleptics in particular 
can lead to the development of extra-pyramidal signs, gait 
abnormalities, sedation, increased incidence of cerebrovas-
cular events, and higher mortality rates (Schneider et al 2005, 
2006; Sink et al 2005).
Building a complex adaptive 
primary care system for dementia
Complex adaptive system (CAS) is an open, dynamic and 
ﬂ  exible network that is considered complex due to its com-
position of numerous interconnected, semi-autonomous, 
competing and collaborating members (McDaniel et al 2003; 
Stoebel et al 2005). The members of CAS can be individuals, 
teams, functional groups, social institutions, or organizational 
processes. The CAS is considered adaptive due to its capabil-
ity of learning from its previous experiences and its ﬂ  exibility 
to accommodate change in the connecting pattern of its 
members (McDaniel et al 2003; Stoebel et al 2005). CAS is 
characterized (see Table 4) by emergent behaviors as opposed 
to predetermined ones and self-organized control instead of 
hierarchical pyramid-based central control (McDaniel et al 
2003; Stoebel et al 2005).
Table 3 Pharmacological management of Alzheimer disease
Class Cognition  ADLs  BPSD
ChEI +  +  +/−
Memantine +  + +
Neuroleptics  −  − +/−
Antidepressants NE  NE  +
Anticonvulsants  −  − +/−
 − ChEI: Cholinesterase inhibitors; +: signiﬁ  cant positive effect; +/−: possible posi-
tive effects; − : negative effect; NE: no effect; All of the neuroleptics are not FDA 
approved for use in Dementia.Clinical Interventions in Aging 2007:2(4) 634
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Health care delivery organizations such as primary 
care clinics are an example of CAS (Stroebel et al 2005). 
These clinics usually include administrative assistants, 
clinic managers, nursing staff, clinical providers, billing 
specialists and other individuals who each bring their own 
perspectives, skills, experiences, and goals to patient care. 
These clinic members interact constantly in a nonlinear way 
and are continually faced with external and internal changes, 
such as patient’s medical status, insurance requirements, 
regulations, new research ﬁ  ndings, member turnover and 
legal issues. Primary care clinics have been described as 
complex adaptive systems with local critical nonlinear 
relationships that produce unpredictable behavioral patterns 
or dynamics (McDaniel et al 2003; Stoebel et al 2005). Any 
attempt to rigidly control this CAS may increase problems 
by paralyzing the members’ ability to learn and take action 
to affect outcomes (McDaniel et al 2003; Stoebel et al 
2005). Although the current system of primary care does 
not have the resources to provide the appropriate diagnosis, 
evaluation, education, and complex management required 
for patients with dementia (Gueerriero Austrom et al 2004; 
Boustani et al 2005; Callahan et al 2006; Schubert et al 2006), 
understanding primary care clinics as a CAS may enhance 
our capacity to develop a ﬂ  exible process of minimally 
standardized approaches to assess and manage patients with 
dementia. Such a process would have the best probability of 
surviving the unknowable future challenges that will face 
these primary care clinics. Over the past decade, Indiana 
University Center for Aging Research used the lens of CAS 
to develop such a collaborative and minimally standardized 
approach to assess and manage patients with dementia 
within a primary care system called PREVENT-Memory 
Loss (Boustani et al 2005; Callahan et al 2006; Guerriero 
Austrom et al 2004). The efﬁ  cacy of PREVENT program 
was evaluated in a randomized controlled trial that enrolled 
153 older adults with Alzheimer disease and included their 
caregivers (Callahan et al 2006).
The PREVENT program included the following 
minimally speciﬁ  ed components: (1) dementia care man-
ager (DCM); (2) electronic tracking of patients status; 
(3) interdisciplinary dementia management resources; 
(4) collaborative work with the patients’ primary care pro-
vider; and (5) caregiver support (see Figure 1). The patients 
were enrolled in PREVENT via a screening and diagnosis 
program for all patients aged 65 and older presenting to their 
primary care physician with or without dementia related 
symptoms. The DCM provided each dyad of patient and 
caregiver with educational material related to the nature of 
Alzheimer disease and community resources. This DCM 
trained the patient’s caregiver in problem solving skills 
related to patients’ functional disability and behavioral and 
psychological symptoms; the DCM was also available to 
the caregivers over the phone or for face-to-face visits at the 
primary care clinic or the patient’s home for any dementia 
related crisis, such as aggressive behaviors and caregiver 
burden. Moreover, the DCM coordinated a monthly care-
giver support meeting that included an exercise program 
for the patients. In addition to consideration for enhancing 
the patient’s cholinergic system via stopping any deﬁ  nite 
anticholinergic medication and initiating treatment with 
cholinesterase inhibitors, the PREVENT interdisciplinary 
resource team developed standard pharmacological and 
non-pharmacological protocols to identify, monitor, and 
treat behavioral and psychological symptoms of dementia 
(Guerriero Austrom et al 2004). In comparison to patients 
randomized to the usual care, PREVENT patients had 
signiﬁ  cantly fewer BPSD (43% vs 71% with P < 0.05) 
(Callahan et al 2006). Furthermore, PREVENT caregiv-
ers reported signiﬁ  cant improvements in their stress and 
depressive symptoms. Such improvement in BPSD was 
not related to higher use of neuroleptics (13% vs 7%, 
p = 0.3) or sedatives (10% vs 9.5%, p = 1.0). However, 
Table 4 Key characteristics of complex adaptive primary care 
system
Members/Agents   Semi-autonomous clinicians,
  administrators, clerks, and patients who
  have the capacity to exchange information 
  with other individuals and with their 
  surrounding environment and subsequently 
  change their behaviors.
Interconnections/  The system members interact locally in
Relationships  nonlinear pattern that lead to rich 
  relationships and network of interrelated 
 individuals
Self-organization  A process that allows the system’s
  members to mutually adjust their
  behaviors to cope with changing internal
  and external environmental demands. Results
  in a new structures and patterns over time
Emergent patterns/  The system self-organizing process may
Emergent behaviors  induce the birth of new system properties,
  features, patterns, and relationships that
  are distinct from the members’ identities,
  properties or features
Co-evolution  A process of reciprocal makeover of both
  the system members and their surrounding
  environment that leads to the creation of
  interdependency of the present and the past
 system’s  experiences. Clinical Interventions in Aging 2007:2(4) 635
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PREVENT patients were more likely to receive ChEIs 
(80% vs 55%, p < 0.01) and antidepressants (45% vs 28%, 
p < 0.05). Despite its impact on BPSD and caregiver stress, 
PREVENT program did not affect the patients’ cognition, 
activities of daily living, or rates of hospitalization, nursing 
home placement or death.
Summary and conclusion
The management of patients with dementia in primary 
care is a challenge to our current health care delivery. 
Redesigning our health care system using the lens of CAS 
to accommodate a program such as PREVENT would 
address this challenge. Healthcare delivery programs 
such as PREVENT enhance the current primary care 
system by integrating a dementia recognition process 
within a dementia management system. To succeed, this 
program must be coordinated by a clinician liaison trained 
in dementia management and supported with access to 
community resources and interdisciplinary specialists in 
dementia care, such as geriatricians, geriatric psychiatrists, 
geriatric neurologists and geriatric psychologists.
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